

### LISTING OF THE CLAIMS

No claims are amended herein. The claims are provided below for the Examiner's convenience.

1. - 30. (Canceled)

31. *(Previously presented)* A pharmaceutical composition formulated for human administration and effective in treating a neoplastic disease or eliciting an anti-tumor immunological response, comprising:

- a) a human cell expressing a cytokine from a recombinant polynucleotide; and
- b) a pharmaceutical excipient;

wherein the cytokine is stably associated in the cell outer membrane, and  
wherein the cell has been inactivated to prevent proliferation.

32. *(Previously presented)* The composition of claim 31, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF- $\alpha$ , and M-CSF.

33. *(Previously added)* The composition of claim 31, wherein the cell is a cancer cell.

34. *(Previously presented)* The composition of claim 31, wherein the cell is from a-tumor of the same tissue type as a tumor in the human.

35. *(Previously presented)* The composition of claim 34, wherein the tumor is an ovarian cancer or a brain cancer.

36. *(Previously presented)* The composition of claim 31, wherein the cell is allogeneic to the human.

37. *(Previously presented)* The composition of claim 31, wherein the cell is histocompatibly identical to the human.

38. *(Previously presented)* The composition of claim 31, further comprising a tumor-associated antigen, wherein the combination of the cytokine and the tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.
39. *(Previously presented)* The composition of claim 38, wherein the tumor-associated antigen is obtained from a cell autologous to the human.
40. *(Previously added)* The composition of claim 38, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.
41. *(Previously presented)* The composition of claim 38, comprising a combination of:  
a) the cell expressing the membrane-associated cytokine; and  
b) a tumor cell autologous to the human;  
wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.
42. *(Previously presented)* The composition of claim 41, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the human.
43. *(Previously added)* The composition of claim 41, wherein the tumor cell is a glioma, a glioblastoma, a gliosarcoma, an astrocytoma, or an ovarian cancer cell.
44. *(Previously presented)* The composition of claim 41, wherein the tumor cell has been inactivated by irradiation.
45. *(Previously presented)* The composition of claim 31, wherein the cell expressing the membrane-associated cytokine has been inactivated by irradiation.

46. *(Previously added)* The composition of claim 31, wherein the cell produces a secreted cytokine in addition to the cytokine stably associated in the outer membrane.
47. *(Previously added)* The composition of claim 31, wherein a majority of the cytokine produced by the cell is present on the outer membrane of the cell.
48. *(Previously presented)* The composition of claim 38, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF- $\alpha$ , and M-CSF.
49. *(Previously presented)* A composition comprising a tumor associated antigen and a population of cells expressing a transmembrane cytokine ,  
wherein the cells have been inactivated to prevent proliferation, and  
wherein the composition is effective in stimulating an immune response to the tumor associated antigen.
50. *(Previously presented)* A unit dose of the composition according to claim 31, wherein the number of cells in the composition is at least about  $5 \times 10^6$  but not more than about  $2 \times 10^8$ .
51. *(Canceled)*
52. *(Previously added)* The composition of claim 31, wherein the cytokine naturally occurs as a membrane cytokine.
53. *(Previously added)* The composition of claim 31, wherein the cytokine is a fusion protein comprising a heterologous transmembrane region.
54. *(Previously added)* The composition of claim 31, wherein the cell has been transduced with a retroviral expression vector, or is the progeny of such a cell.

55. *(Previously added)* A method for producing the composition of claim 31, comprising transducing the cell with an expression vector encoding the membrane-associated cytokine.
56. *(Previously added)* The method of claim 55, wherein the expression vector is a retroviral vector.
57. *(Previously presented)* The method of claim 55, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF- $\alpha$ , and M-CSF.
58. *(Previously added)* The method of claim 55, wherein the cytokine is expressed under control of a cytomegalovirus (CMV) promoter.
59. *(Previously presented)* The method of claim 55, wherein the cell is from a cancer of the same tissue type as a tumor in the human.
60. *(Previously presented)* The method of claim 55, wherein the cell is allogeneic to the human.
61. *(Previously presented)* The method of claim 55, wherein the cell is histocompatibly identical to the human.
62. *(Previously added)* A method for producing the composition of claim 38, comprising transducing a cell with an expression vector encoding the membrane-associated cytokine, and providing the transduced cell in combination with the tumor-associated antigen.
63. *(Previously presented)* The method of claim 55, further comprising inactivating the cell to prevent proliferation.
64. *(Previously presented)* The method of claim 55, further comprising irradiating the cell.

65. *(Previously presented)* The composition of claim 31, wherein the cytokine is IL-4.
66. *(Previously presented)* The composition of claim 31, wherein the cytokine is GM-CSF.
67. *(Previously presented)* The composition of claim 31, wherein the cytokine is M-CSF.
68. *(Previously presented)* A pharmaceutical composition effective in treating a neoplastic disease or eliciting an anti-tumor immunological response, comprising:
- a) a human cell expressing a cytokine from a recombinant polynucleotide; and
  - b) a pharmaceutical excipient;
- wherein the cytokine is stably associated in the cell outer membrane, and  
wherein the composition has been formulated for administration to an allogeneic human subject.
69. *(Previously presented)* The composition of claim 68, wherein the cytokine is selected from IL-4, GM-CSF, IL-2, TNF- $\alpha$ , and M-CSF.
70. *(Previously presented)* The composition of claim 68, wherein the cell is a cancer cell.
71. *(Previously presented)* The composition of claim 68, wherein the cell is from a tumor of the same tissue type as a tumor in the human.
72. *(Previously presented)* The composition of claim 68, further comprising a tumor-associated antigen, wherein the combination of the cytokine and the tumor-associated antigen in the composition is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.
73. *(Previously presented)* The composition of claim 72, wherein the tumor-associated antigen is obtained from a cell autologous to the human.

74. *(Previously presented)* The composition of claim 72, wherein the tumor-associated antigen is expressed by the same cells expressing the membrane-associated cytokine.
75. *(Previously presented)* The composition of claim 72, comprising a combination of:  
a) the cell expressing the membrane-associated cytokine; and  
b) a tumor cell autologous to the human;  
wherein the combination is effective in treating a neoplastic disease or eliciting an anti-tumor immunological response in the human.
76. *(Previously presented)* The composition of claim 75, wherein the tumor cell is a primary tumor cell dispersed from a solid tumor obtained from the human.
77. *(Previously presented)* The composition of claim 68, wherein the cell expressing the membrane-associated cytokine has been inactivated by irradiation.
78. *(Previously presented)* A method for producing the composition of claim 68, comprising transducing the cell with an expression vector encoding the membrane-associated cytokine.
79. *(Previously presented)* The method of claim 78, wherein the expression vector is a retroviral vector.
80. *(Previously presented)* The method of claim 78, further comprising inactivating the cell to prevent proliferation.
81. *(Previously presented)* The method of claim 78, further comprising irradiating the cell.

82 (New) A pharmaceutical composition formulated for human administration and effective in treating a neoplastic disease or eliciting an anti-tumor immunological response, comprising:

- a) a human cell expressing a cytokine from a recombinant polynucleotide; and
- b) a pharmaceutical excipient;

wherein the cytokine is stably associated in the cell outer membrane, and

wherein the cell has been inactivated to prevent proliferation, and wherein the number of cells in the composition is at least about  $5 \times 10^6$ .